AUPH Stock Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aurinia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.82 |
| 52 Week High | US$12.43 |
| 52 Week Low | US$4.71 |
| Beta | 1.38 |
| 1 Month Change | -6.95% |
| 3 Month Change | -39.75% |
| 1 Year Change | -54.61% |
| 3 Year Change | -61.81% |
| 5 Year Change | -22.01% |
| Change since IPO | 135.12% |
Recent News & Updates
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Recent updates
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
May 20Shareholder Returns
| AUPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | -4.7% | -3.7% |
| 1Y | -54.6% | -2.7% | 20.2% |
Return vs Industry: AUPH underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: AUPH underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| AUPH volatility | |
|---|---|
| AUPH Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AUPH's share price has been volatile over the past 3 months.
Volatility Over Time: AUPH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 300 | Peter Greenleaf | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Aurinia Pharmaceuticals Inc. Fundamentals Summary
| AUPH fundamental statistics | |
|---|---|
| Market cap | US$697.06m |
| Earnings (TTM) | -US$78.02m |
| Revenue (TTM) | US$175.51m |
4.0x
P/S Ratio-8.9x
P/E RatioIs AUPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUPH income statement (TTM) | |
|---|---|
| Revenue | US$175.51m |
| Cost of Revenue | US$21.68m |
| Gross Profit | US$153.83m |
| Other Expenses | US$231.85m |
| Earnings | -US$78.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 87.65% |
| Net Profit Margin | -44.45% |
| Debt/Equity Ratio | 0% |
How did AUPH perform over the long term?
See historical performance and comparison